Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

NCT06241807 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

IMMUNOTHERAPY
Neoadjuvant Therapy
Resectable Lung Non-Small Cell Carcinoma
Biomarkers / Blood

Interventions

DRUG: Camrelizumab Plus Chemotherapy

Sponsor

Shandong Cancer Hospital and Institute